Michael A. Patmas, MD, MS
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Patmas M.; Treatment of Erythema Migrans. Ann Intern Med. 1997;126:408. doi: 10.7326/0003-4819-126-5-199703010-00014
Download citation file:
Published: Ann Intern Med. 1997;126(5):408.
TO THE EDITOR:
I had the privilege of participating in the study by Luft and colleagues . The data on the rate of complete resolution of erythema migrans in amoxicillin recipients may have been overstated. My patient, a 75-year-old man, was enrolled in the study in July 1991 when he presented with an engorged, embedded deer tick surrounded by an erythema migrans rash in the right popliteal fossa. This patient received and was fully compliant with treatment. His rash cleared within a few weeks, and he was considered to be a complete responder. About 1 month later, he developed internuclear ophthalmoplegia associated with several areas of increased signal intensity on magnetic resonance imaging of the brain. This was thought to be due to microvascular disease. In October 1991, the patient developed complete heart block and required insertion of a pacemaker. The attending cardiologist did not consider Lyme disease, and I was not notified of this development until December 1991. The patient was next seen in May 1992, when he presented with synovitis and effusion involving his knees and ankles. By July 1992, I was concerned that this patient had not been cured of Lyme disease and communicated my concerns to Pfizer Central Research. It is not clear from the article by Luft and colleagues  whether this particular patient was still considered a complete responder, was considered a treatment failure, or was excluded from evaluation. Clarification of this issue is needed before the data on response rates can be considered reliable.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only